Investigational Tx shows promise for NMIBC: 48% complete response rate for BCG-refractory disease observed.
| Publicado en: | Urology Times Vol. 46; no. 8; p. 18 |
|---|---|
| Autor principal: | |
| Formato: | brief item pictorial Journal Article |
| Publicado: |
MJH Life Sciences
Aug2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131215662&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 131215662 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00939722 URO jtl: Urology Times issn: 00939722 maglogo: N pubinfo: dt: Aug2018 vid: 46 iid: 8 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 131215662 131215662 131215662 131215662 ppf: 18 ppct: 0 formats: fmt: @attributes: type: P tig: atl: Investigational Tx shows promise for NMIBC: 48% complete response rate for BCG-refractory disease observed. aug: au: Schieszer, John sug: subj: Bladder Neoplasms Therapy Neoplasm Invasiveness Therapy Muscle Neoplasms Therapy BCG Vaccine pubtype: Academic Journal doctype: brief item pictorial Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|